Pharmacokinetics of multiple-dose administration of eltenac in horses.

This research investigated the pharmacokinetics of eltenac in horses to determine if any changes occurred between the first and final intravenous administrations. It was found that there was no significant accumulation of eltenac in the horse’s blood or changes to its pharmacokinetics after multiple 0.5 mg/kg doses.

Study Design and Methodology

The study included the following design and methodology:

• Six adult mares were given an intravenous (IV) dose of eltenac every 24 hours for five consecutive days. The dosage was calculated at 0.5 mg/kg of body weight.
• Blood samples were collected on the first and last day of administration – both before administering the dose and at periodic intervals over an eight-hour period post-administration.
• The concentration of eltenac in these plasma samples was identified using a process called high-performance liquid chromatography, a method used to separate the components in a mixture, to measure the concentration of such substances.

Results

• On both the first (day 0) and last day (day 4) of eltenac administration, the median area under the curve (AUC), a parameter used in pharmacokinetics to determine the total body exposure to a drug, was found to be similar (6.77 microg.h/ml and 6.70 microg.h/ml, respectively).
• Similarly, the median plasma clearance rate, which measures how quickly the drug is eliminated from the body, and the median steady-state volume of distribution, a pharmacokinetic term referring to the apparent volume in which a drug is distributed in the body, were roughly the same on both days.
• The terminal half-life of eltenac, or the time it takes for the concentration of the drug in the body to reduce by half, was approximately 2.36 hours on the first day and 2.40 hours on the last day.
• The study also found that eltenac displayed high protein binding capacity, indicating that the drug readily binds to proteins in the blood.

Conclusions

• The pharmacokinetic variables determined were not found to be significantly different between the first and last day, indicating that there might not be any important accumulation of the drug in the horses’ bodies with multiple doses.
• The research concluded that under the conditions of this study, no clinically significant accumulation of eltenac or alterations to its pharmacokinetic variables were detected after multiple intravenous doses of 0.5 mg/kg of the substance.

This research provides valuable insights into the pharmacokinetics of eltenac in horses following multiple dosing.